Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 312
Selected: 0
NCT IDTitle
NCT01522170aHUS Observational Long Term Follow-Up
NCT05346354Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
NCT00935883Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)
NCT02003144An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
NCT01095887Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation
NCT04935294Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction
NCT00742859Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin
NCT04557735Study of Ravulizumab in Pediatric Participants With HSCT-TMA
NCT06578949Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT01192425Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes
NCT05501717Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants
NCT01528917An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype
NCT01192399Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
NCT04195763Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)
NCT04564339Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
NCT02496689Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)
NCT06374264Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder
NCT00844428Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS
NCT04802083COVID-19 Soliris Expanded Access Protocol
NCT01194804E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
NCT07557420Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT03053102Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT02112994Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency
NCT05389449A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
NCT07218887ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
NCT02207725A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban
NCT00375609Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
NCT05259085Study of ALXN2050 in Participants With Hepatic Impairment
NCT00034359Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
NCT05303324Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults
NCT04980248Study of ALXN1850 in Participants With Hypophosphatasia (HPP)
NCT02987504Study of Samalizumab in Patients With Advanced Cancer
NCT07352423Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants
NCT01106027Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant
NCT03124368A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
NCT03384186A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants
NCT01849562Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants
NCT04551599A Study of the Effects of Food and Age on Danicopan
NCT02235493Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09
NCT02598583Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT00844545Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS
NCT07337395Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab
NCT03329365Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS
NCT02013037The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
NCT01765855An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects
NCT05202145Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
NCT01757431The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT00088179Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
NCT07413679Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
NCT01194973An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome